CN103189041B - Fingernail or toenail growth composition for promoting - Google Patents
Fingernail or toenail growth composition for promoting Download PDFInfo
- Publication number
- CN103189041B CN103189041B CN201180053494.4A CN201180053494A CN103189041B CN 103189041 B CN103189041 B CN 103189041B CN 201180053494 A CN201180053494 A CN 201180053494A CN 103189041 B CN103189041 B CN 103189041B
- Authority
- CN
- China
- Prior art keywords
- fingernail
- toenail
- valproic acid
- growth
- salt pharmaceutically
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q3/00—Manicure or pedicure preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses and comprise valproic acid or its salt pharmaceutically allowed as the fingernail of effective ingredient or toenail growth composition for promoting.In addition, the pharmaceutical composition containing described compositions and cosmetic composition is also related to.
Description
Technical field
The present invention relates to fingernail or toenail growth composition for promoting.
Background technology
Fingernail and toenail are the hard and thin tablet being attached to finger or toe end respectively, are changed by keratodermatitis.The main constituent of fingernail and toenail is called keratic protein, and during known increase protein uptake amount, the speed of growth of fingernail and toenail is accelerated.
The speed of growth of usual fingernail is faster than toenail, and it is according to there being fingernail centrifugal closely dirty, the saying that thus blood circulation is fast and be subject to the saying of relatively many stimulations, but does not also open correct reason.In addition, the fingernail of known modern and the speed of growth of toenail are compared ever-faster, propose owing to being the basis that modern absorbs caused by more protein this.
Summary of the invention
The invention provides fingernail or toenail growth composition for promoting.In addition, fingernail or toenail growth is also provided to promote pharmaceutical composition or cosmetic composition.
One aspect of the present invention provides a kind of fingernail or toenail growth composition for promoting, wherein, comprises valproic acid or its salt pharmaceutically allowed as effective ingredient.
The present invention on the other hand provides a kind of pharmaceutical composition, wherein, containing comprising described valproic acid or its salt pharmaceutically the allowed compositions as effective ingredient.
In addition, another aspect of the invention provides a kind of cosmetic composition, wherein, containing comprising described valproic acid or its salt pharmaceutically the allowed compositions as effective ingredient.
Compositions according to an aspect of the present invention comprises valproic acid or its salt pharmaceutically allowed as effective ingredient, thus can promote the growth of fingernail or toenail.Described compositions not only can need to use when promoting the growth of fingernail or toenail due to the reason in beauty treatment etc. at normal object, can also due to fingernail or toenail disease and the poor growth of the fingernail of object or toenail time, the purposes grown to promote it and using.As mentioned above, the fingernail of the object suffering from fingernail or toenail disease or the growth of toenail can be promoted, thus the treatments period of fingernail or toenail disease can be shortened, improve therapeutic effect.
Accompanying drawing explanation
Fig. 1 be to represent before coating (0 day) to coating after 10 days (10 days) and before coating to coating the chart of the experimental group (left side) of (20 days) and the fingernail growth length of matched group (right side) after 20 days.
Fig. 2 is the photo of the fingernail extent of growth represented according to coating duration, and a is the fingernail photo before coating, and b is the fingernail photo of coating after 10 days, and c is the fingernail photo of coating after 20 days.Being respectively left side fingernail is experimental group, and right side fingernail is matched group.
Detailed description of the invention
When suffering from fingernail or toenail disease, the poor growth of fingernail or toenail, treatment time extends thereupon, and described fingernail or toenail disease can enumerate tinea unguium, fingernail loses and supports disease or fingernail separation disease etc. as an example.Such as, when suffering from tinea unguium, the poor growth of fingernail or toenail, so the general antifungal needing more than 6 months long-term taking itraconazoles (itraconazole) or fluconazol (fuluconazole) and so on.These medicines may cause hepatic injury and be unsuitable for long-term taking.Therefore, when promoting compositions and the antifungal coupling of fingernail or toenail growth, from the viewpoint of during can shortening the taking of antifungal being favourable.
The following detailed description of the present invention.
One aspect of the present invention demonstrates valproic acid or its salt pharmaceutically allowed has the excellent effect promoting fingernail or toenail growth, and providing package is containing its fingernail as effective ingredient or toenail growth composition for promoting.
As the effective ingredient of compositions according to an aspect of the present invention and valproic acid (the valproic acid used, 2-propylpentanoic acid) used as Anticonvulsants in epilepsy therapy in the past, also manic depression is used as mood stabilizer (mood stabilizer).The reaction of known valproic acid induction various kinds of cell, but also cannot know definitely and what mechanism to alleviate spasm by and to suppress Deviant Behavior.
According to an aspect of the present invention, valproic acid or its salt pharmaceutically allowed are not particularly limited, such as, can be sodium valproate (sodium valproate).
According to an aspect of the present invention, take composition total weight as benchmark, valproic acid or its salt pharmaceutically allowed can containing 0.5 ~ 30 % by weight.According to a further aspect of the invention, take composition total weight as benchmark, valproic acid or its salt pharmaceutically allowed can containing 1.0 ~ 20 % by weight.According to another aspect of the invention, with the gross weight of compositions for benchmark, valproic acid or its salt pharmaceutically allowed can containing 3.0 ~ 10 % by weight.With above-mentioned % by weight containing sometimes, be not only applicable to display expected effect of the present invention, stability and the safety of compositions can also be met, also suitablely in cost performance to contain with above-mentioned scope.Particularly, with the gross weight of compositions for benchmark, valproic acid or its salt pharmaceutically allowed are less than 0.5 % by weight and containing sometimes, be difficult to the growth result expecting sufficient fingernail or toenail; More than 30 % by weight containing sometimes, the stability of compositions may reduce.
Above-mentioned composition according to an aspect of the present invention can be exterior-applied formulation.Above-mentioned composition according to a further aspect in the invention can be at specific part, such as, want the topical formulations that the fingernail of growth promoting effects or local, toenail position use.Now, can utilize can the Topical Drug Delivery Systems (local drug diliverysystem) of real maximum efficiency in desired location with a small amount of compositions.
An aspect of of the present present invention provides a kind of pharmaceutical composition, wherein, containing comprising valproic acid or its salt pharmaceutically the allowed compositions as effective ingredient.Particularly, described pharmaceutical composition can promote the fingernail of the patient suffering from fingernail or toenail disease or the growth of toenail.Described fingernail or toenail disease comprise tinea unguium, fingernail loses and supports disease or fingernail separation disease.
Material useful on the salt that described pharmaceutical composition can also comprise antiseptic, stabilizing agent, wettable powder or emulsification promoter, regulate for osmotic pressure and/or the pharmacy adjuvant such as buffer agent and other treatment, dosage form can turn to the form of multiple oral administration agent or non-oral administration agent by usual way.Particularly, described pharmaceutical composition can use with exterior-applied formulation.
Described oral administration agent has such as tablet, pill, hard and soft capsules, liquor, suspensoid, emulsifying agent, syrup, powder, powder, microgranule, granule, pellet (pellet) etc., and these dosage forms can also contain surfactant, diluent (such as: lactose, glucose, sucrose, mannitol, sorbitol, cellulose or glycine), lubrication prescription (such as: silicon dioxide, Talcum, stearic acid and magnesium salt thereof or calcium salt or Polyethylene Glycol) except effective ingredient.Tablet can also comprise the bonding agent of aluminium-magnesium silicate, gelatinized corn starch, gelatin, Tragacanth, methylcellulose, sodium carboxymethyl cellulose or polyvinylpyrrolidine and so on, can also contain the pharmacy additives such as the disintegrating agent of starch, agar, alginic acid or its sodium salt and so on, absorbent, coloring agent, flavouring agent or sweeting agent as required.Described tablet can by common mixing, granulating or coating process manufacture.
Described non-oral administration agent can be the such as dosage form such as injection, some drop, ointment, emulsion, gel, frost, spraying, suspensoid, Emulsion, suppository, patch, but is not limited thereto.
Described according to an embodiment of the invention pharmaceutical composition can pass through per os, non-per os such as rectum, locally, percutaneous, intravenous, intramuscular, intraperitoneal, the administration such as subcutaneous.
In addition, the pharmaceutically admissible consumption of described effective ingredient, namely dosage can be different according to the judgement of the order of severity of the age for the treatment of target, sex, body weight, the specified disease that need treat or pathological state, disease or pathological state, route of administration or prescriptionist.Dosage based on these factors can be decided by those skilled in the art.Common dosage be 0.01mg/kg/ day ~ 2000mg/kg/ day, preferred 1mg/kg/ day ~ 100mg/kg/ day, but above-mentioned dosage not delimit the scope of the invention.
One aspect of the present invention provides a kind of cosmetic composition, wherein, containing comprising valproic acid or its salt pharmaceutically the allowed compositions as effective ingredient.
Described cosmetic composition can be such as cosmetics, and the profile of cosmetics can comprise medium or the substrate of cosmeceutical or Dermatology permission.This is that all dosage forms that can use to be suitable for local provide, such as, emulsion, complex emulsions, suspension, microemulsion, microcapsule, subparticle ball, ion-type (liposome) and the nonionic folliculus dispersion of in the emulsion of disperseing oil phase to obtain in solution, gel, solid, the anhydrous product of pulpous state, aqueous phase, oil phase, disperseing aqueous phase to obtain, foam (foam) or the aerosol composition form containing compressed propellant.These compositionss can be manufactured by usual way by those skilled in the art.
Cosmetic composition can also comprise fatty material, organic solvent, concentrating agents, gelating agent, softening agent, antioxidant, suspensoid, stabilizing agent, foaming agent (foaming agent), aromatic, surfactant, water, ion-type or nonionic emulsifier, filler, metal ion chelation agent, chelating agen, preservative agent, vitamin, blocker, wetting agent, required oil, dyestuff, pigment, hydrophilic or lipophile activating agent, lipid folliculus or cosmetics or the normally used auxiliary agent of dermatology.Described auxiliary agent imports with cosmeceutical or the normally used amount of dermatology.
Described cosmetic composition, without particular limitation of dosage form, suitably can select dosage form as required.Such as, more than one the dosage form be selected from astringent, emulsion, elite, frost, ointment, colloidal sol, facial film, patch, spray, powder, screening flaw rod, hands or foot emulsion, hands or foot frost, hands or foot oil, hands or foot elite, hands or foot lotion, cleansing cream, clean emulsion, cleaning foam and clean water can be fabricated to, but be not limited thereto.
By the following examples and experimental example further describe formation of the present invention and effect.But following examples and experimental example are only provide with illustrative object to help to understand the present invention, and category of the present invention and scope do not limit thus.
The manufacture of [embodiment] sodium valproate solution
According to the composition of following table 1, comprise the solution of sodium valproate as embodiment by usual way manufacture.
[table 1]
| Composition | Content |
| HPMC K100MC | 1.0 |
| Purified water | 79.2 |
| Sodium valproate | 8.3 |
| Ethanol | 10.0 |
| Polysorbas20 (Tween20) | 1.0 |
| BHT | 0.5 |
| Add up to | 100 |
[experimental example] fingernail growth result is evaluated
By the embodiment solution (experimental group) of above-mentioned manufacture and identical with other compositions of embodiment but with purified water replace the solution of sodium valproate (matched group) be coated on respectively left side and right side little finger fingernail, with go to bed after Wound healing and bone regeneration dressing membrane parcel (left: experimental group, right: matched group).Experimental session implements coating with interval once a day.Before measuring coating, coating is after 10 days and coating growth length of fingernail after 20 days, takes a picture.Photograph result image J software is analyzed.Its result illustrates in fig. 1 and 2.Fig. 1 represents that coating is after 10 days and the chart of length of coating growth of fingernail after 20 days, Fig. 2 be represent coating before (a), the photo of the degree of the growth of (c) fingernail after (b) and coating 20 days after coating 10 days.
As shown in Figures 1 and 2, can confirm that experimental group compares matched group fingernail, extent of growth is large.That is, sodium valproate has the effect promoting fingernail growth.Particularly can confirm in Fig. 1 and Fig. 2, As time goes on, the fingernail growth result that sodium valproate causes increases.
Be described the dosage form example of compositions of the present invention below, but also can be applied as other various dosage forms, it only for illustrating the present invention, does not limit the present invention.
[dosage form example 1] frost
[table 2]
| Gradation composition | Content (% by weight) |
| Sodium valproate | 5.0 |
| Glycerol | 3.0 |
| Butanediol | 3.0 |
| Liquid paraffin | 7.0 |
| Beta glucan | 7.0 |
| Carbomer | 0.1 |
| Caprylic/capric triglyceride | 3.0 |
| Squalane | 5.0 |
| Cetearyl glucoside | 1.5 |
| Sorbitan stearate | 0.4 |
| Polysorbate 60 | 1.2 |
| Triethanolamine | 0.1 |
| Antiseptic, pigment, spice | In right amount |
| Purified water | Surplus |
[dosage form example 2] ointment
[table 3]
| Composition | % by weight |
| Caprylic/capric triglyceride | 10 |
| Liquid Paraffin | 10 |
| Sorbitan sesquioleate | 6 |
| Octyl dodecanol polyethers-25 | 9 |
| Spermol ethylhexoate | 10 |
| Squalane | 1 |
| Salicylic acid | 1 |
| Glycerol | 15 |
| Sorbitol | 1 |
| Sodium valproate | 2 |
| Antiseptic, pigment, spice | In right amount |
| Purified water | Surplus |
[dosage form example 3] liquor
Sodium valproate ... ... ... ... ... ... ... .100mg
Isomerized sugar ... ... ... ... ... ... ... ... .10g
Mannitol ... ... ... ... ... ... ... ... ..5g
Vitamin C ... ... ... ... ... ... ... ... 50mg
Serine ... ... ... ... ... ... ... ... .50mg
Oils and fats ... ... ... ... ... ... ... .... appropriate
Purified water ... ... ... ... ... ... ... .... surplus
According to common liquor manufacture method, in purified water, add each component dissolves, after adding appropriate NINGMENGXIANG, mentioned component is mixed, then adds purified water, integrally-regulated for 100ml by what add after purified water, then be filled in brown bottle, carry out sterilizing, thus manufacture liquor.
Claims (7)
1. valproic acid or its salt pharmaceutically allowed promote the application in the compositions of fingernail or toenail growth in preparation.
2. the application of valproic acid according to claim 1 or its salt pharmaceutically allowed, wherein, described valproic acid or its salt pharmaceutically allowed are sodium valproate.
3. the application of valproic acid according to claim 1 or its salt pharmaceutically allowed,
Wherein, with described composition total weight for benchmark, described compositions comprises valproic acid or its salt pharmaceutically allowed of 0.5 ~ 30 % by weight.
4. the application of valproic acid according to claim 1 or its salt pharmaceutically allowed,
Wherein, described compositions is external preparation.
5. the application of valproic acid according to any one of claim 1 to 4 or its salt pharmaceutically allowed,
Wherein, described compositions is pharmaceutical composition.
6. the application of valproic acid according to claim 5 or its salt pharmaceutically allowed,
Wherein, described pharmaceutical composition is for the growth of the fingernail or toenail that promote the patient suffering from fingernail or toenail disease.
7. the application of valproic acid according to any one of claim 1 to 4 or its salt pharmaceutically allowed,
Wherein, described compositions is cosmetic composition.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2010-0097376 | 2010-10-06 | ||
| KR1020100097376A KR101733189B1 (en) | 2010-10-06 | 2010-10-06 | Composition for promotion of growing nail or toenail |
| PCT/KR2011/007352 WO2012047007A2 (en) | 2010-10-06 | 2011-10-05 | Composition for promoting fingernail or toenail growth |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103189041A CN103189041A (en) | 2013-07-03 |
| CN103189041B true CN103189041B (en) | 2015-09-30 |
Family
ID=45928213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201180053494.4A Active CN103189041B (en) | 2010-10-06 | 2011-10-05 | Fingernail or toenail growth composition for promoting |
Country Status (3)
| Country | Link |
|---|---|
| KR (1) | KR101733189B1 (en) |
| CN (1) | CN103189041B (en) |
| WO (1) | WO2012047007A2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102021734B1 (en) * | 2018-05-24 | 2019-09-16 | 김선희 | Correcting method for ingrowing nail and protective coating agent used the method |
| WO2020025683A1 (en) * | 2018-08-01 | 2020-02-06 | Edix-O Sarl | Injectable prolonged-action compositions for use in the treatment of nail disease and/or for promoting nail growth |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL72381A (en) | 1983-07-20 | 1988-03-31 | Sanofi Sa | Pharmaceutical composition based on valproic acid |
| SI1311256T1 (en) * | 2000-08-17 | 2005-12-31 | Teva Pharma | Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment or prevention of pain and/or headache disorders |
| EP1293205A1 (en) | 2001-09-18 | 2003-03-19 | G2M Cancer Drugs AG | Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease |
| EP1839656A1 (en) | 2006-03-31 | 2007-10-03 | TopoTarget Germany AG | Use of valproic acid for the topical treatment of mild to moderate acne vulgaris |
-
2010
- 2010-10-06 KR KR1020100097376A patent/KR101733189B1/en active IP Right Grant
-
2011
- 2011-10-05 CN CN201180053494.4A patent/CN103189041B/en active Active
- 2011-10-05 WO PCT/KR2011/007352 patent/WO2012047007A2/en active Application Filing
Non-Patent Citations (2)
| Title |
|---|
| FERAH ARMUTCU et.al..《Effect of Long-Term Therapy with Sodium Valproate on Nail and Sodium Trace Element Status in Epileptic Children》.《Biological Trace Element Research》.2004,第102卷1-10. * |
| 陆小左 等.《看甲知健康》.《看甲知健康》.2009,6. * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012047007A3 (en) | 2012-07-05 |
| WO2012047007A2 (en) | 2012-04-12 |
| KR20120035691A (en) | 2012-04-16 |
| CN103189041A (en) | 2013-07-03 |
| KR101733189B1 (en) | 2017-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1765356B2 (en) | Spray composition comprising a combination of calcitriol and clobetasol propionate, an alcoholic phase, at least one volatile silicone and one non volatile oily phase | |
| US20070292461A1 (en) | Oleaginous pharmaceutical and cosmetic foam | |
| CN102256666B (en) | A composition and method of treating skin conditions | |
| EP3125857A1 (en) | Compositions and methods for enhancing the topical application of a basic benefit agent | |
| JP2010530400A5 (en) | ||
| CN108524479A (en) | Include the composition for external application of ceramide | |
| EA023887B1 (en) | Foam formulation comprising a pickering emulsion | |
| KR20170123698A (en) | Multi-layer cosmetic composition | |
| US10675234B1 (en) | Systems and methods for treating and/or preventing acne | |
| ES2302060T3 (en) | SPRAY COMPOSITION INTENDED TO ADMINISTER DERIVATIVES OF VITAMIN D. | |
| US10828250B2 (en) | Topical formulation | |
| CN102639127A (en) | Composition for skin improvement comprising hexamidines and retinoids | |
| JP5866279B2 (en) | Composition for preventing hair loss or promoting hair growth | |
| US7763655B2 (en) | Cosmetic compositions having carnitine creatinate and methods for using | |
| KR20220010508A (en) | Formulations and methods for preparing stable cosmetic compositions | |
| CN106999384A (en) | Cleasing compositions | |
| KR102120416B1 (en) | Composition comprising high concentration caffeines | |
| CN103189041B (en) | Fingernail or toenail growth composition for promoting | |
| EP2398489A2 (en) | Composition comprising n2 - (1-oxohexadecyl) - lysyl - valyl - lysine for treating rosacea and its symptoms | |
| JPH08127518A (en) | Composition for hair | |
| JPWO2020138403A1 (en) | External composition for skin and aerosol | |
| JP2013523787A (en) | Use of dihydrodehydrodiisoeugenol and formulations containing dihydrodehydrodiisoeugenol | |
| JP2020158493A (en) | Water-in-oil type (w/o type) cream containing panthenol | |
| JP2009215274A (en) | Powdery hair growth agent applied to various spots of body except head | |
| CN107530253B (en) | Composition containing psoralen for promoting hair growth and/or hair growth |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |